Easton Pharmaceuticals Inc.

September 22, 2011 09:00 ET

Easton Pharmaceuticals Announces Retaining Winston & Strawn For Patent Application Submission

TORONTO, ONTARIO--(Marketwire - Sept. 22, 2011) - Easton Pharmaceuticals Inc (OTC:EAPH), a specialty pharmaceutical company that designs, develops, and markets topically-delivered healthcare products, announces it has retained Winston & Strawn LLP as its patent attorneys for a patent application submission directed to its Viorra brand product and proprietary transdermal technology.

A retainer was advanced after a consultation with the firm to act as its patent attorneys on an anticipated patent application submission. Winston & Strawn is a large multinational law firm. The firm's patent attorneys, including those based in Washington, D.C., are well versed with all types of patent filings including pharmaceutical and OTC transdermal type of products such as the "Viorra" brand product.

The 'Viorra' brand product is a cosmeceutical retail product that the company anticipates to launch in North America, South America, Mexico and East Asian markets. Viorra™ is expected to be Easton Pharmaceuticals first product to market which is a non-invasive topical treatment intended to assist women suffering from a range of Female Sexual Arousal Disorders (FSAD), including physical conditions that cause a lack of vaginal elasticity, lubricity and sensation.

Viorra As An Alternative To Ineffective Hormonal Therapies

"Millions of women have discovered that traditional hormonal therapies offered by the pharmaceutical industry for the past 50 years are simply not effective in allowing women to enjoy normal sexual intimate pleasure and sensation," stated John Easton C.E.O and Chairman of the Board of Easton Pharmaceuticals. "Most women do not want to use a 'drug' for these conditions. Viorra is an over-the-counter topical gel that is safe, effective, and with daily use restores a woman's vaginal lubricity, and assists in improved sensation.

$5.5 Billion Market

A publicly-traded company listed on the NASDAQ and the OTCPK, Easton Pharmaceuticals is targeting the estimated $2 billion market for FSAD. Easton is also developing a pipeline of transdermal products using the VD™ technology in Viorra for a variety of applications including topical treatments for women and men seeking to diminish scars, adhesions, cellulite, varicose veins, and stretch marks. The Company believes these additional applications target an estimated $3.5 billion market for treatments to diminish the appearance of damaged and aging skin which Easton's subsequent products will address. Easton Pharmaceuticals will shortly announce its management team of highly credentialed physicians, medical researchers, and pharmaceutical industry professionals, and will focus on rapid revenue-growth through an aggressive mix of traditional distribution channel-supported retail sales and emerging Internet-based marketing and sales opportunities.

About Easton Pharmaceuticals Inc

Easton Pharmaceuticals is a specialty pharmaceutical company that designs, develops, and markets a premium array of topically-delivered therapeutic healthcare products. The company's VDX proprietary gel formulation is an innovative and unique transdermal delivery system. Easton Pharmaceuticals' flagship product, Viorra, is an over-the-counter aid for the treatment of FSAD. Viorra is a topical, daily-use product containing Generally Regarded as Safe (GRAS) ingredients.

For more information, visit: www.eastonpharmaceuticals.com

Safe Harbor

This news release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (The "Act"). In particular, when used in the preceding of discussion, the words "pleased," "plan," "confident that," "believe," "expect," or "intent to" and similar conditional expressions are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company's products and technologies, competitive factors, the ability to successfully complete additional financing and other risks in the company's financial reports and filings.

Source: Easton Pharmaceuticals Inc.

Contact Information